Purpose: To report the use of commercially available preservative-free intrav itreal triamcinolone acetonide for the treatment of macular oedema due to retina l vascular diseases. Design: Retrospective interventional case series. Methods: Charts of eyes that received 4 mg preservative-free intravitreal triamcinolone acetonide for the treatment of persistent macular oedema due to retinal vascular diseases were reviewed. Patients were included if they had a follow-up of at least 3 months. Visual acuity, intraocular pressure, presence of an anterior cha mber reaction, and mean macular thickness on optical coherence tomography (OCT) were recorded. Results: A total of 10 eyes of 10 patients were identified. Visua l acuity improved by a mean of 1.1 Suellen lines at 1 month and 1.3 lines at 3 m onths. Macular thickness on OCT decreased by a mean of 183.5 μm at 1 month (P< 0.0001). Intraocular pressure increased from a mean of 13.5 mmHg at baseline to 15.3 at 1 month, and 14.5 at 3 months. Only the 1-month change in intraocular p ressure was statistically significant (P=0.0274). There were no cases of endopht halmitis, anterior chamber reaction, or retinal detachment. Conclusion: In this small retrospective, noncomparative series, commercially available preservative -free intravitreal triamcinolone acetonide had no adverse outcomes. Macular oed ema was noted to decrease following treatment.
展开▼
